Lantern Pharma appoints Lee T. Schalop to Board, reduces shareholder quorum to 33.33%

Lantern Pharma Inc.

Appointed Lee T. Schalop, M.D., former CEO of Oncoceutics (sold to Chimerix for $450M), to the Board effective July 24, 2025.
Dr. Schalop has extensive biotech and finance background including roles at Morgan Stanley, J.P. Morgan, Credit Suisse.
Board amended By-laws to reduce stockholder quorum requirement from majority to one-third (33.33%) of shares entitled to vote.
Amendment to Section 2.07 effective immediately on July 24, 2025.

item 5.02item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.